These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 21855119)
21. Correlation of survivin and MMP9 expressions with prognosis and clinicopathological parameters in surface epithelial ovarian carcinomas. Kuşku Cabuk F; Yığıt S; Demır L; Cakalağaoğlu F; Tarhan O Turk Patoloji Derg; 2014; 30(1):30-7. PubMed ID: 24448704 [TBL] [Abstract][Full Text] [Related]
22. The Association Between Talc Use and Ovarian Cancer: A Retrospective Case-Control Study in Two US States. Cramer DW; Vitonis AF; Terry KL; Welch WR; Titus LJ Epidemiology; 2016 May; 27(3):334-46. PubMed ID: 26689397 [TBL] [Abstract][Full Text] [Related]
23. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. Gao J; Yang X; Zhang Y Jpn J Clin Oncol; 2015 Jan; 45(1):49-60. PubMed ID: 25387732 [TBL] [Abstract][Full Text] [Related]
25. Temporal trends in the incidence and relative survival of non-small cell lung cancer in Canada: A population-based study. Akhtar-Danesh N; Finley C Lung Cancer; 2015 Oct; 90(1):8-14. PubMed ID: 26215032 [TBL] [Abstract][Full Text] [Related]
26. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Matz M; Coleman MP; Sant M; Chirlaque MD; Visser O; Gore M; Allemani C; Gynecol Oncol; 2017 Feb; 144(2):405-413. PubMed ID: 27931752 [TBL] [Abstract][Full Text] [Related]
27. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma. Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276 [TBL] [Abstract][Full Text] [Related]
28. Effects of access to and treatment in specialist facilities on survival from epithelial ovarian cancer in Australian women: a data linkage study. Tracey E; Hacker NF; Young J; Armstrong BK Int J Gynecol Cancer; 2014 Sep; 24(7):1232-40. PubMed ID: 25153678 [TBL] [Abstract][Full Text] [Related]
29. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
30. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. van Altena AM; Karim-Kos HE; de Vries E; Kruitwagen RF; Massuger LF; Kiemeney LA Gynecol Oncol; 2012 Jun; 125(3):649-54. PubMed ID: 22370602 [TBL] [Abstract][Full Text] [Related]
32. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival. Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491 [TBL] [Abstract][Full Text] [Related]
33. Survival in ovarian cancer patients by histology and family history. Ji J; Försti A; Sundquist J; Lenner P; Hemminki K Acta Oncol; 2008; 47(6):1133-9. PubMed ID: 18607880 [TBL] [Abstract][Full Text] [Related]
34. Green tea consumption enhances survival of epithelial ovarian cancer. Zhang M; Lee AH; Binns CW; Xie X Int J Cancer; 2004 Nov; 112(3):465-9. PubMed ID: 15382073 [TBL] [Abstract][Full Text] [Related]
35. Oral Contraceptive Use and Reproductive Characteristics Affect Survival in Patients With Epithelial Ovarian Cancer: A Cohort Study. Kolomeyevskaya NV; Szender JB; Zirpoli G; Minlikeeva A; Friel G; Cannioto RA; Brightwell RM; Grzankowski KS; Moysich KB Int J Gynecol Cancer; 2015 Nov; 25(9):1587-92. PubMed ID: 26273932 [TBL] [Abstract][Full Text] [Related]
36. Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type? Kajiyama H; Shibata K; Mizuno M; Umezu T; Suzuki S; Yamamoto E; Fujiwara S; Kawai M; Nagasaka T; Kikkawa F Int J Gynecol Cancer; 2012 Mar; 22(3):394-9. PubMed ID: 22391762 [TBL] [Abstract][Full Text] [Related]
37. The impact of geographic variations in treatment on outcomes in ovarian cancer. Dehaeck U; McGahan CE; Santos JL; Carey MS; Swenerton KD; Kwon JS Int J Gynecol Cancer; 2013 Feb; 23(2):282-7. PubMed ID: 23295939 [TBL] [Abstract][Full Text] [Related]
38. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002. Hannibal CG; Cortes R; Engholm G; Kjaer SK Acta Obstet Gynecol Scand; 2008; 87(12):1353-60. PubMed ID: 18951210 [TBL] [Abstract][Full Text] [Related]
39. Ovarian cancer outcomes: Predictors of early death. Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531 [TBL] [Abstract][Full Text] [Related]
40. Non-aspirin NSAID use and ovarian cancer mortality. Verdoodt F; Dehlendorff C; Friis S; Kjaer SK Gynecol Oncol; 2018 Aug; 150(2):331-337. PubMed ID: 29960709 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]